Osteodysplasia
Conditions
Keywords
Bone marrow transplant, bone marrow stromal cells, allogeneic transplant, Osteodysplasia, Osteogenesis imperfecta, Gene marking, Stromal cell
Brief summary
Osteodysplasia or poorly formed bones, brittle bones is a genetic disease with no known proven treatments. Some forms of osteodysplasia may cause severe disability and even death. Eligible patients were limited to those children with Osteodysplasia who had undergone a previous allogeneic bone marrow transplant at St. Jude. The study intervention involved an infusion of a specified number of ex vivo expanded stromal cells obtained from the bone marrow of the same donor from whom they received their primary transplant procedure. These bone marrow stromal cells can become bone-forming cells, called osteoblasts. Participants then received 2 infusions of ex vivo expanded, gene marked cells not less than 6 months after bone marrow transplantation. The second cell infusion occurred between 14 to 21 days after the first infusion in the absence of toxicity. The goal of the study was to evaluate the safety and toxicity of these infusions.
Detailed description
* To determine whether these ex vivo expanded, gene marked marrow stromal cells will engraft in the recipient's bone, bone marrow, and/or skin. * To begin to investigate whether high proliferative mesenchymal progenitor cells can be expanded ex vivo and retain their progenitor potential in vivo. * To begin to investigate whether ex vivo expanded bone marrow stromal cells can ameliorate the skeletal dysplasias associated with various genetic disorders.
Interventions
BIOLOGICALMarrow stromal cell infusion
This is a pilot study of infusions of ex vivo expanded, gene marked donor bone marrow stromal cells following allogeneic bone marrow transplantation. The study is a within patient dose escalation safety evaluation. It is believed that this patient population may benefit from these donor stromal cell infusions. As the stromal cells will be obtained from the original stem cell donor, no conditioning is required. Patients will receive two infusions of mesenchymal cells (MSC) approximately 14 to 21 days apart unless there is unacceptable toxicity after the first infusion. The first dose of cells to be given will be 1x10\^6 MSC/kg and the second dose of cells will be 5x10\^6 MSC/kg. The patients will be followed for approximately 28 days following the second infusion for any toxicity. Only after all six patients have safely completed both infusions will we consider 5 x 10\^6 MSC/kg a safe dose of allogeneic mesenchymal stem cells for infusion.
Sponsors
Drexel University
Wayne State University
St. Jude Children's Research Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients with an appropriate genetic disorder who have had an allogeneic bone marrow transplant and currently maintain complete or mixed hematopoietic chimerism * Patient must be \< or equal to 18Kg
Exclusion criteria
* Presence of infection * Presence of GVHD (graft versus host disease)or the need for prophylaxis * Concurrent participation in any investigational study that could potentially confound the interpretation of the safety parameters being investigated in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the safety of the stromal cell infusion | June 2001 |
Countries
United States
Outcome results
None listed